{
    "N/R/U": null,
    "Applicant": "Eli Lilly and Company",
    "BLA Number": "761306",
    "Proprietary Name": "Ebglyss",
    "Proper Name": "lebrikizumab-lbkz",
    "BLA Type": "351(a)",
    "Strength": "250MG/2ML",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Autoinjector",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "13-Sep-24",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "1891",
    "Product Number": "1",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}